CANDEL THERAPEUTICS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
CANDEL THERAPEUTICS, INC. (CADL) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 16.85 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 16.51M shares.
- CANDEL THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 14.93M shares, a 9.76% increase year-over-year.
- CANDEL THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 13.60M shares, a 3.39% increase year-over-year.
- CANDEL THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2022-09-30 was 13.70M shares, a 12.52% increase year-over-year.
- CANDEL THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 14.01M shares, a 13.67% increase from fiscal 2024.
- CANDEL THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 12.32M shares, a 21.50% decline from fiscal 2023.
- CANDEL THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 15.70M shares, a 14.06% increase from fiscal 2022.
- CANDEL THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 13.77M shares, a 12.00% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 16.85M shares 10-Q · filed 2026-08-13 | ||||
| 2026-03-31 | 16.51M shares 10-Q · filed 2026-05-14 | ||||
| 2025-12-31 | 14.01M shares 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | 13.72M shares 10-Q · filed 2025-11-13 | ||||
| 2025-06-30 | 13.64M shares 10-Q · filed 2026-08-13 | ||||
| 2024-12-31 | 12.32M shares 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | 13.34M shares 10-Q · filed 2025-11-13 | ||||
| 2024-06-30 | 13.79M shares 10-Q · filed 2025-08-14 | ||||
| 2024-03-31 | 14.93M shares 10-Q · filed 2025-05-13 | ||||
| 2023-12-31 | 15.70M shares 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | 14.18M shares 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | 14.54M shares 10-Q · filed 2024-08-13 | ||||
| 2023-03-31 | 13.60M shares 10-Q · filed 2024-05-14 | 12.99M shares 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | 13.77M shares 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | 13.70M shares 10-Q · filed 2022-11-10 | 13.70M shares 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 13.16M shares 10-Q · filed 2022-08-05 | 13.16M shares 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | 13.15M shares 10-Q · filed 2023-05-11 | 13.33M shares 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | 12.29M shares 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | 12.17M shares 10-Q · filed 2022-11-10 | 12.17M shares 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | 19.13M shares 10-Q · filed 2022-08-05 | 19.13M shares 10-Q · filed 2022-08-05 | |||
| 2021-03-31 | 18.69M shares 10-Q · filed 2022-05-12 | ||||
| 2020-12-31 | 18.64M shares 10-K · filed 2022-03-29 | ||||
| 2020-09-30 | 15.62M shares 10-Q · filed 2021-11-12 | 15.62M shares 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | 15.62M shares 10-Q · filed 2021-09-08 | 15.62M shares 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |